Journal
SEMINARS IN IMMUNOLOGY
Volume 23, Issue 3, Pages 214-219Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2011.07.003
Keywords
Type 1 diabetes; Autoantibodies; Immunotherapy; T cells; Tolerance
Categories
Funding
- National Institutes of Diabetes & Digestive & Kidney Diseases [R01 DK055969]
- National Institutes of Health Diabetes & Endocrinology Research Core [P30 DK057516]
- National Institute of Allergy & Infectious Diseases [U519 AI050864-08]
- Juvenile Diabetes Foundation [4-2007-1056, 17-2010-744]
- Brehm Coalition
- Children's Diabetes Foundation
Ask authors/readers for more resources
Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the specific immune destruction of insulin producing beta cells. Currently there is no cure for T1D and treatment for the disease consists of lifelong administration of insulin. Immunotherapies aimed at preventing beta cell destruction in T1D patients with residual c-peptide or in individuals developing T1D are being evaluated. Networks of researchers such as TrialNet and the Immune Tolerance Network in the U.S. and similar networks in Europe have been established to evaluate such immunotherapies. This review focuses on immune intervention for the prevention and amelioration of human T1D with a focus on potential immune suppressive, antigen specific and environmental therapies. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
